You are here

Article Text

Article menu

Download PDFPDF

E-Poster viewings
Cervical Cancer
IGCS19-0264
148 Senticol III: international validation study of sentinel node biopsy in early cervical cancer. A gineco, engot and gcig study
Free
  1. F Lecuru1,
  2. M Mc Comack2,
  3. P Hillemans3,
  4. A Anota4,
  5. M Leitao5,
  6. R Sweemer6,
  7. K Fujiwara7,
  8. P Mathevet8,
  9. V Zanagnolo9,
  10. M Raza Mirza10,
  11. G Ferron11,
  12. M Plante12 and
  13. V Balaya13
  1. 1Georges Pompidou european Hospital, Gynecologic oncology, PARIS, France
  2. 2University College Hospital, Radiation therapy, London, UK
  3. 3Hannover Klinik fur Frauenheilkunde, gynecologic oncology, Hannover, Germany
  4. 4CHRU Besancon, Statistics, Besancon, France
  5. 5Memorial Sloan Kettering Cancer Center, Gynecologic Oncology, New York, USA
  6. 6UMC Utrecht, Gynecologic Oncology, Utrecht, Netherlands Antilles
  7. 7Saitama Medical University Center, Gynecologic Oncology, Saitama, Japan
  8. 8CHU Vaudois, Gynecologic Oncology, Lausanne, Switzerland
  9. 9Istituto Europeo di Oncologia, Gynecologic Oncology, Milan, Italy
  10. 10Rigshospitalet, Gynecologic Oncology, Copenhagen, Norway
  11. 11Oncopole, Gynecologic Oncology, Toulouse, France
  12. 12CHU Quebec, Gynecologic Oncology, Quebec, Canada
  13. 13Georges Pompidou European Hospital, Gynecologic and Breast Oncologic Surgery Department, Paris, France

Abstract

Objectives The aim of the present study is to demonstrate a similar survival and a better quality of life when compared to PLN.

Methods SENTICOL III is an international prospective multicenter randomized trial.

The primary objective is a « co-primary » objective associating Disease Free Survival (DFS) and Health Related Quality of Life. The hypothesis is that SLN biopsy alone provides similar DFS and better quality of life.

Outcome of patients with ITC and micrometastases will belong to secondary objectives (with overall survival, recurrence free survival, cost analysis, etc.).

Patients with squamous or adenocarcinoma from FIGO 2018 stage Ia1 with lymphovascular invasion to Ib2 and IIa1, will be included. SLN mapping will use isotopic detection ± blue dye or ICG. Frozen section of SLN will be done in case of “optimal” mapping. Patients with negative SLN will be randomized intraoperatively 1:1 to SLN only or SLN + PLN. A quality assurance program will ensure surgical competency and a standardized pathological evaluation.

950 patients have to be included in 3 years, with 4 years of follow-up. (3 years-disease free survival of 85%, with a non-inferiority margin of 5% (80 vs 85%, HR = 1.373), a unilateral alpha error of 5%, and a power of 80%).

Results Inclusions are open in France, and an international collaboration has been developed through GCIG and ENGOT. (NCT03386734). CHU Besançon is the sponsor for France

Conclusions A validation study is needed for early cervical cancer. SENTICOL III will answer the question of the deescalation for nodal staging.

https://doi.org/10.1136/ijgc-2019-IGCS.148

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.